InterMune Inc

    [td_text_with_title custom_title=”Company description”]InterMune Inc. is a publicly traded (Ticker: ITMN) biotechnology company, which has its Global headquarters in San Francisco in the United States and its European headquarters in Switzerland. Our focus is on the research and development of innovations in the field of respiratory and orphan fibrotic diseases. In respiratory, the company are focused on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease.

    As a result of our focused research, in February 2011, Esbriet® (pirfenidone) was approved by the European Commission for use in patients with mild to moderate IPF. Pirfenidone is the only medicine approved for IPF anywhere in the world and InterMune is currently running a Phase 3 clinical trial to support regulatory registration in the United States. InterMune’s research programmes are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases.[/td_text_with_title]


    Posts not found

    [td_text_with_title custom_title=”Latest post”]

    Posts not found